Edition:
United Kingdom

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,578JPY
12:22am GMT
Change (% chg)

¥-48 (-1.85%)
Prev Close
¥2,626
Open
¥2,550
Day's High
¥2,590
Day's Low
¥2,550
Volume
578,100
Avg. Vol
2,399,413
52-wk High
¥2,734
52-wk Low
¥2,185

Latest Key Developments (Source: Significant Developments)

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

National Investments Fund - Celyad enters into license agreement with ono pharmaceutical co., ltd. to develop allogeneic nkr-2 t-cell immunotherapy<1227.HK><4528.T>
Wednesday, 13 Jul 2016 

National Investments Fund Ltd <1227.HK>: Celyad enters into license agreement with Ono Pharmaceutical Co., Ltd. to develop allogeneic nkr-2 t-cell immunotherapy . Celyad would receive upfront payment of $12.5 million and is eligible of up to $299 million in development and commercial milestones . Celyad would also receive double digit royalties based on net sales of the licensed product in ono's territories . Under the agreement, Celyad would continue developing its allogeneic nkr-2 t-cell immunotherapy in EU and US territories . Says company is aware that Celyad s.a had published a press release on 11 July 2016 .  Full Article

Celyad says early signing agreement with ONO is because of interest of companies - conf call
Monday, 11 Jul 2016 

Celyad SA : Reason for early signing agreement with ONO Pharmaceutical <4528.T> is because of interest of companies to do so - conf call . In order for deal in US or Europe, would have to be "extremely compelling" for us at this stage - conf call . Within next 12 months we should expect second milestone - conf call . Royalty rate is same for all 3 countries - conf call . On C-Cure: discussions with EMA in Q3 - conf call . Japanese partnership has been relatively expedited - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Celyad enters into license agreement with ONO Pharmaceutical
Monday, 11 Jul 2016 

Celyad SA : Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. <4528.T> to develop allogeneic NKR-2 T-cell immunotherapy . Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan . Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories. . Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories . Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million) . Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones .Will also receive double digit royalties based on net sales of licensed product in ONO's territories.  Full Article

ONO PHARMACEUTICAL raises consolidated full-year outlook for FY 2016
Tuesday, 2 Feb 2016 

ONO PHARMACEUTICAL CO LTD:Says the company increased the consolidated full-year outlook for revenue to 156,000 mln yen from 144,500 mln yen, for the fiscal year ending March 31, 2016.Operating profit forecast increased to 24,000 mln yen from 15,200 mln yen.Net profit forecast increased to 18,600 mln yen from 13,100 mln yen.Earnings per share increased to 175.46 yen from 123.58 yen.Comments the increased sales of core products as the main reason for the forecast.  Full Article

BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

* Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs